Search results for "blood coagulation tests"

showing 7 items of 27 documents

Fatal cerebellar haemorrhage due to phenprocoumon poisoning.

1996

A 32-year-old patient died of a cerebellar haemorrhage and the blood coagulation analysis before death suggested defective synthesis of vitamin K-dependent clotting factors due to vitamin K deficiency. The post-mortem toxicological examination of different tissues revealed phenprocoumon poisoning as the cause of death. The differential diagnosis of vitamin K deficiency and the toxicology of hydroxycoumarins are discussed.

VitaminAdultMalemedicine.medical_specialtyBrain DeathPoison controlGastroenterologyPathology and Forensic MedicinePhenprocoumonchemistry.chemical_compoundCerebellar DiseasesInternal medicineVitamin K deficiencyMedicineHumansCause of deathCerebral HemorrhageClotting factorDose-Response Relationship Drugbusiness.industryWarfarinBrainmedicine.diseaseSurgerychemistryPhenprocoumonVitamin K DeficiencyBlood Coagulation TestsDifferential diagnosisDrug Overdosebusinessmedicine.drugInternational journal of legal medicine
researchProduct

Effective hemostasis during minor surgery in a case of hereditary combined deficiency of vitamin K-dependent clotting factors.

2009

Combined deficiency of the vitamin K-dependent clotting factors (VKCFD) is a rare bleeding disorder involving defective gamma-carboxylation of coagulation factors II , VII, IX and X as well as natural anticoagulants protein C and protein S. The disease is characterized by a cluster of different, often life threatening, bleeding symptoms occurring both spontaneously and in a surgical setting. In the present paper we describe two different treatment modalities to be used both in a programmed surgical procedure and in an emergency scenario. As this disease is a natural model that resembles oral anticoagulation, our experience discloses a possible rationale in the use of recombinant activated …

VitaminAdultmedicine.medical_specialtyVitamin KBiopsyFactor VII DeficiencyHereditary Combined Deficiency of Vitamin K-dependent Clotting FactorsBlood Loss SurgicalDiseaseFactor VIIaGastroenterologyMixed Function Oxygenaseschemistry.chemical_compoundBlood Coagulation Disorders InheritedInternal medicineVitamin K Epoxide ReductasesGastroscopymedicineHumansRare Inherited Bleeding disorders Minor SurgeryOral anticoagulationClotting factorbusiness.industryHomozygoteWarfarinHematologyGeneral MedicineFactor VIIHemostasis SurgicalRecombinant ProteinsSurgeryCoagulationchemistryHemostasisTooth ExtractionFemaleBlood Coagulation TestsbusinessProtein Cmedicine.drugClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
researchProduct

Blood Coagulation and Thrombosis in Patients with Ovarian Malignancy

1997

SummaryOvarian cancer cells appear to be capable of both thrombin formation and induction of fibrin degradation which may be essential prerequisites for the development of deep vein thrombosis (DVT) as well as the spread of malignancy. To study further this coagulation – cancer interaction in 60 patients with untreated ovarian cancer of FIGO stage I-IV the incidence of DVT was recorded pre-operatively, postoperatively on day 1, 3, 5, 7, 10, before each of six cycles of Cisplati- num/Epirubicin/Cyclophosphamide chemotherapy, during follow-up and in the post-operative period of second look surgery. In addition, blood coagulation tests results were determined prospectively. Two patients were e…

medicine.medical_specialtymedicine.drug_classLow molecular weight heparinGastroenterologyPostoperative ComplicationsMedian follow-upThromboembolismInternal medicinemedicineHumansProspective Studiescardiovascular diseasesBlood CoagulationAgedBlood coagulation testOvarian NeoplasmsUnivariate analysisHeparinbusiness.industryAntithrombinAnticoagulantAnticoagulantsHematologyHeparinHeparin Low-Molecular-WeightMiddle AgedSurvival AnalysisSurgeryFemaleBlood Coagulation Testsbusinessmedicine.drugEpirubicinThrombosis and Haemostasis
researchProduct

Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials

2018

Abstract Background Prediction models for venous thromboembolism recurrence will likely be improved by adding levels of coagulation factors. Risk assessment is ideally performed during anticoagulant treatment, however, the influence of direct oral anticoagulants on coagulation factors is uncertain. Objective To assess the influence of rivaroxaban and apixaban on several coagulation factor levels. Methods In two crossover trials we assessed the influence of rivaroxaban and apixaban intake on factor (F)VIII, FXI and FXII‐activity and fibrinogen, von Willebrand factor (VWF:Ag), and d‐dimer levels. At three sessions with a washout period in between, blood was taken from 12 healthy male individu…

medicine.medical_specialtymedicine.drug_mechanism_of_actionFactor Xa Inhibitorapixabanfactor Xa inhibitors030204 cardiovascular system & hematologyTreatment resultsFibrinogenGastroenterology03 medical and health sciences0302 clinical medicineVon Willebrand factorInternal medicinecoagulantsMedicinerivaroxabanBlood coagulation testRivaroxabanbiologybusiness.industryBrief Reportblood coagulation testsrisk assessmentHematologyCoagulation030220 oncology & carcinogenesisbiology.proteinApixabanbusinessOriginal Articles: Thrombosismedicine.drug
researchProduct

Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants.

2018

BACKGROUND AND PURPOSE Whereas intravenous thrombolysis (IVT) is allowed for acute ischaemic stroke in patients on vitamin K antagonists with international normalized ratio ≤1.7, there are no similar recommendations for patients on direct oral anticoagulants (DOACs), notably due to the lack of coagulation tests to assess the therapeutic effects. Although the literature is scarce, consisting of small case series and retrospective studies, considering the frequency of this situation the French Vascular Neurology Society and the French Study Group on Haemostasis and Thrombosis have worked on a joint position paper to provide a practical position regarding the emergency management of ischaemic …

medicine.medical_specialtymedicine.medical_treatmentAdministration Oral030204 cardiovascular system & hematologyAntithrombinsDabigatranBrain Ischemia03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRivaroxabanAtrial FibrillationCoagulation testingMedicineHumansThrombolytic TherapyStrokeRetrospective StudiesProthrombin timeRivaroxabanmedicine.diagnostic_testbusiness.industryAnticoagulantsIdarucizumabThrombolysismedicine.diseaseDabigatranStrokeNeurologyEmergency medicineAdministration IntravenousNeurology (clinical)Blood Coagulation Testsbusiness030217 neurology & neurosurgeryPartial thromboplastin timemedicine.drugFactor Xa InhibitorsEuropean journal of neurology
researchProduct

F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes.

2022

Background Circulating dysfunctional factor IX (FIX) might modulate distribution of infused FIX in hemophilia B (HB) patients. Recurrent substitutions at FIX activation sites (R191-R226, >300 patients) are associated with variable FIX activity and antigen (FIXag) levels. Objectives To investigate the (1) expression of a complete panel of missense mutations at FIX activation sites and (2) contribution of F9 genotypes on the FIX pharmacokinetics (PK). Methods We checked FIX activity and antigen and activity assays in plasma and after recombinant expression of FIX variants and performed an analysis of infused FIX PK parameters in patients (n = 30), mostly enrolled in the F9 Genotype and PK HB …

medicine.medical_specialtypharmacogenetics.Mutation MissenseSocio-culturaleAlpha (ethology)aemophilia Brecombinant proteinsHemophilia Blaw.inventionFactor IXAntigenlawInternal medicineGenotypemedicineMissense mutationHumansHaemophilia BpharmacokineticBeta (finance)Factor IXpharmacogeneticsChemistryHematologymedicine.diseaseEndocrinologyPhenotypefactor IX activation; hemophilia B; pharmacogenetics; pharmacokinetics; recombinant proteinsRecombinant DNAFemalefactor IX activationBlood Coagulation Testspharmacokineticsrecombinant proteinmedicine.drugJournal of thrombosis and haemostasis : JTH
researchProduct

Interaction of allopurinol with phenprocoumon in man.

1977

Conditions in two patients on long-term phenprocoumon (Marcumar®) treatment are reported who had signs of phenprocoumon overdosage when given simultaneously allopurinol. The determination of phenprocoumon plasma concentrations in one patient showed that phenprocoumon accumulates for several weeks during treatment with allopurinol. Signs of phenprocoumon overdosage thus can appear long time after starting allopurinol treatment.

musculoskeletal diseasesAdultMalecongenital hereditary and neonatal diseases and abnormalitiesAllopurinolMyocardial InfarctionAllopurinolPharmacologyPhenprocoumonDrug DiscoveryMedicineHumansDrug InteractionsBlood CoagulationGenetics (clinical)integumentary systembusiness.industrynutritional and metabolic diseasesGeneral Medicine4-HydroxycoumarinsDrug interactionMiddle AgedPlasma concentrationPhenprocoumonMolecular MedicineBlood Coagulation TestsbusinessMathematicsmedicine.drugKlinische Wochenschrift
researchProduct